The 5th Digital DDR, ATR & PARP Inhibitors Summit is coming at a timely inflection point within this field. With Wee1 & ATR approvals on the horizon and countless novel targets currently undergoing exciting pre-clinical validation, this unique and highly anticipated meeting unites the world experts in DDR inhibition to propel this space through the barriers it faces to clinical breakthrough.  

This industry-led forum once again evolves to reflect progress in the DDR therapies field with focused content on:

  • PARP Inhibition: Next-Gen PARPi’s, PARP Resistance & the Future of PARP Inhibitors
  • Developing Clinically Successful Wee1 & ATR Inhibitors for Cancer Therapy
  • Exploring the Strategy, Execution, Development & Promise of the Emerging Targets: Polθ, WRN, CHK1, DNA-PK, USP1, PARG, ATM, PKMYT1
  • Identifying Reliable DDR/HR Tumor Biomarkers
  • Managing Toxicity -  Optimizing Patient Selection, Therapeutic Window & Treatment Regimes
  • Developing Predictive Pre-Clinical Models in DDR to Achieve Human-Specific Translation
  • Novel Methodologies, Genetic Screening & Imaging Technologies to Revolutionize Pathway Understanding, Compound Optimization & Clinical Translation
  • Next Steps in Combination Approaches: to Heighten Drug Effect & Overcome Resistance 

2022 World-Class Speaker Faculty

Testimonials

“Meeting to be for everyone involved in DDR drug research!”

Merck & Co

 

“There really isn’t another conference like this mainly focused on PARP and DDR translational research.”

EMD Serono

 

“Great summary of the DDR field with interesting discussions and updates on latest data”

Novartis

2022 Partners Included:

Snapshot of Previous Attendees Included

PARP Companies attending (1)